Literature DB >> 12555936

Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

J Weglage1, D Wiedermann, J Denecke, R Feldmann, H G Koch, K Ullrich, H E Möller.   

Abstract

Recent studies indicate that individual blood-brain transport characteristics of phenylalanine may lead to different clinical outcomes in phenylketonuria (PKU) patients in spite of comparable dietary control. To check these preliminary data, we investigated four pairs of siblings with classical PKU (and identical genotype) using in vivo nuclear magnetic resonance spectroscopy in the course of an oral phenylalanine load (100 mg/kg body weight). Patients' brain phenylalanine concentrations were different in spite of similar blood levels. Interindividual variations of the apparent transport Michaelis constant, Kt,app, ranged from 0.10 to 0.84 mmol/L. The ratio of the maximal transport velocity, Tmax, over the intracerebral consumption rate, Vmet, varied between 2.61 and 14.0. Siblings with lower values for Kt,app, higher values for Tmax/Vmet, and higher concurrent brain phenylalanine levels showed a lower IQ and a higher degree of cerebral white matter abnormalities. The results indicate that blood-brain barrier transport characteristics and the resultant brain phenylalanine levels are causative factors for the individual clinical outcome in PKU.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555936     DOI: 10.1023/a:1021234730512

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  6 in total

1.  Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria.

Authors:  A Rupp; R Kreis; J Zschocke; J Slotboom; C Boesch; D Rating; J Pietz
Journal:  J Cereb Blood Flow Metab       Date:  2001-03       Impact factor: 6.200

2.  Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria.

Authors:  G M Knudsen; S Hasselbalch; P B Toft; E Christensen; O B Paulson; H Lou
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Blood-brain phenylalanine relationships in persons with phenylketonuria.

Authors:  R Koch; R Moats; F Guttler; P Guldberg; M Nelson
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

4.  Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; E Harms; H E Möller
Journal:  Ann Neurol       Date:  2001-10       Impact factor: 10.422

5.  Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria.

Authors:  H E Möller; J Weglage; D Wiedermann; K Ullrich
Journal:  J Cereb Blood Flow Metab       Date:  1998-11       Impact factor: 6.200

6.  In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment.

Authors:  H E Möller; P Vermathen; K Ullrich; J Weglage; H G Koch; P E Peters
Journal:  Neuropediatrics       Date:  1995-08       Impact factor: 1.947

  6 in total
  12 in total

Review 1.  Imaging of neurogenetic and neurometabolic disorders of childhood.

Authors:  Andrea Gropman
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

2.  Adult-onset phenylketonuria revealed by acute reversible dementia, prosopagnosia and parkinsonism.

Authors:  Francesca Rosini; Alessandra Rufa; Lucia Monti; Letizia Tirelli; Antonio Federico
Journal:  J Neurol       Date:  2014-10-31       Impact factor: 4.849

3.  Nuclear magnetic resonance spectroscopy in glutaryl-CoA dehydrogenase deficiency.

Authors:  O A Bodamer; S Gruber; S Stöckler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 4.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

5.  Improved Measurement of Brain Phenylalanine and Tyrosine Related to Neuropsychological Functioning in Phenylketonuria.

Authors:  Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin
Journal:  JIMD Rep       Date:  2016-09-28

6.  1H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU).

Authors:  Paul E Sijens; Matthijs Oudkerk; Dirk-Jan Reijngoud; Klaas L Leenders; Harold W de Valk; Francjan J van Spronsen
Journal:  Eur Radiol       Date:  2004-08-03       Impact factor: 5.315

Review 7.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

Review 8.  Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism.

Authors:  S Kölker; S W Sauer; G F Hoffmann; I Müller; M A Morath; J G Okun
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

9.  Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study.

Authors:  Eszter Juhász; Erika Kiss; Erika Simonova; Attila Patócs; Peter Reismann
Journal:  Eur J Med Res       Date:  2016-05-11       Impact factor: 2.175

10.  Age-related psychophysiological vulnerability to phenylalanine in phenylketonuria.

Authors:  Vincenzo Leuzzi; Daniela Mannarelli; Filippo Manti; Caterina Pauletti; Nicoletta Locuratolo; Carla Carducci; Claudia Carducci; Nicola Vanacore; Francesco Fattapposta
Journal:  Front Pediatr       Date:  2014-06-23       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.